how about danaher.g in part because it's pivoted in into biopharma space you have to wonder what that meant for danaher that is just buying g.e.'s biopharma unit in cash they raised a secondary and the stock went right up after the secondary. it was fabulous opportunity. i like this situation. dan scherr a great track record when it comes to making acquisitions, and i'm betting this one will be like all the other terrific deals they've done that i have a whole system that lets them turn good businesses into great ones that's one reason the stock is up a staggering 35% for the year i think danaher could have even more upside. again, how about buy some here and wait for the pullback. it's not just the big boys there has been tons of smaller winners in the life science space. how about this one avantor. have you seen this it came public may 17th. oh, i love this kind of stock. the ipo priced at 14 the stock didn't generate much excitement opened at $14.50 now it's rallied to 18 it has more room to run. the